The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
Open accessAbstract
Background Despite remarkable results with salvage standard-dose or high-dose chemotherapy ∼15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of immunotherapy in patients with GCT.Patients and methods Single arm phase II trial investigating pembrolizumab 200 mg i.v. Q3weeks until disease progression in patients with relapsed GCT and no curable options. Patients age ≥18 with GCT who progressed after first-line cisplatin-based chemotherapy and after at least one salvage regimen (high-dose or standard-dose chemotherapy) were eligible. Centrally assessed programmed death-ligand 1 (PD-L1) on tumor and infiltrating immune cells was scored. Primary end point was overall response rate using immune-related response criteria. Simon two-stage design with type I error 20% and power 80% was utilized.Results Twelve male patients were enrolled. Median age was 38 years. All patients had nonseminoma. Primary site was testis (11) or mediastinum (1). Median AFP 615 (range 1-32, 760) and hCG 4 (range 0.6-37, 096). Six patients had late relapse (>2 years). Median number of previous chemotherapy regimens was 3. Six patients received prior high-dose chemotherapy. Two patients had positive PD-L1 staining (H-score 90 and 170). Median number of pembrolizumab doses was 2 (range 1-8). There were six grade 3 adverse events. No immune-related adverse events were reported. No partial or complete responses were observed. Two patients achieved radiographic stable disease for 28 and 19 weeks, respectively; both had continued rising AFP level despite radiographic stability and had negative PD-L1 staining.Conclusion This is the first reported trial evaluating immune checkpoint inhibitors in GCT. Pembrolizumab is well tolerated but does not appear to have clinically meaningful single-agent activity in refractory GCT.Clinical trial information NCT02499952.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“their corresponding tumors lacked PD-L1 expression on immunochemical staining [50].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“In the course of this study, there were no partial or complete response noted.”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“both of these patients exhibited ongoing increases in AFP levels despite radiographic stability”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“Among the total of 12 patients, only two of them experienced radiographically stable disease, which persisted for 28 and 19 weeks, respectively.”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Self-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067749 · Cited by 496
Self-citationKondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., Bosl, G. J., & Motzer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.638 · Cited by 418
Cited by
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450
Self-citationRuan, H., Hu, Q., Wen, D., Chen, Q., Chen, G., Lu, Y., Wang, J., Cheng, H., Lu, W., & Gu, Z. (2019) · Advanced Materials · doi:10.1002/adma.201806957 · Cited by 220
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Zhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937612 · Cited by 207
Metadata
- Authors
- Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H.
- Affiliations
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center (US)
- Indiana University School of Medicine (US)
- Hoosier Cancer Research Network (United States) (US)
- Abramson Cancer Center (US)
- Corresponding author
- Adra, N.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 29
- Issue
- 1
- Pages
- 209-214
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2765537501
- Cited by
- 196
- References
- 28
- Citations by year
- 2026: 18 · 2025: 11 · 2024: 28 · 2023: 19 · 2022: 18 · 2021: 29 · 2020: 24 · 2019: 28 · 2018: 18
- FWCI
- 20.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 722 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Testicular diseases and treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- pembrolizumab, germ cell tumors, non-seminoma, platinum-refractory disease, immune checkpoint inhibitors, PD-L1 expression, immunotherapy, overall response rate, alpha-fetoprotein, immune-related adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Adult, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Humans, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Biomarkers, Tumor, Salvage Therapy, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. https://app.cochat.ai/papers/10.1093/annonc/mdx680
- The paper
- Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H. (2018). Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Annals of Oncology. https://doi.org/10.1093/annonc/mdx680
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.